Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Serum CYR61 Levels are Associated with Graves' Ophthalmopathy and Smoking in Patients with Graves' Disease

Cerri, Perparim LU ; Shahida, Bushra LU ; Lantz, Mikael LU and Planck, Tereza LU (2021) In Hormone and Metabolic Research 54(3). p.168-174
Abstract

Smoking is a well-known risk factor for Graves' ophthalmopathy (GO) in patients suffering from Graves' disease (GD). Cysteine-rich angiogenic inducer 61 (CYR61), which has multiple physiological functions, has been shown to be associated with GD and GO. In this study, we aimed to investigate the association between smoking and CYR61 concentrations in GD patients with and without GO. Serum CYR61 was measured by ELISA. The association between CYR61 concentration and GO was assessed with binary logistic regression in all patients and in subgroups of smokers and nonsmokers. The Spearman correlation coefficient was used to determine the correlations between CYR61 concentration and clinical parameters. CYR61 levels were significantly higher... (More)

Smoking is a well-known risk factor for Graves' ophthalmopathy (GO) in patients suffering from Graves' disease (GD). Cysteine-rich angiogenic inducer 61 (CYR61), which has multiple physiological functions, has been shown to be associated with GD and GO. In this study, we aimed to investigate the association between smoking and CYR61 concentrations in GD patients with and without GO. Serum CYR61 was measured by ELISA. The association between CYR61 concentration and GO was assessed with binary logistic regression in all patients and in subgroups of smokers and nonsmokers. The Spearman correlation coefficient was used to determine the correlations between CYR61 concentration and clinical parameters. CYR61 levels were significantly higher in GD patients with GO than in patients without GO, in smokers than in nonsmokers and in individuals older than 50 years than in those younger than 50 years. The subgroup of GO smokers had the highest CYR61 levels [median (IQR), 119 pg/ml (129.8)], compared with GO nonsmokers [84.2 pg/ml (90.8), p=0.04], no GO smokers [88.9 pg/ml (109.8), p=0.01] and no GO nonsmokers [79.4 pg/ml (129.89), p=0.003]. For each unit increase in CYR61 concentration, the odds of having GO in smokers significantly and independently increased by 1% (OR=1.010; 95% CI: 1.002-1.018, p=0.012). In conclusion, our results indicate that smoking and age increase serum CYR61 levels in patients with GD and GO. The role of CYR61 as a predictor of GO in patients with GD should be evaluated in prospective studies.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
CCN1, CYR61, Graves' disease, Graves' ophthalmopathy, immediate early genes, smoking
in
Hormone and Metabolic Research
volume
54
issue
3
pages
7 pages
publisher
Georg Thieme Verlag
external identifiers
  • scopus:85126388857
  • pmid:35276742
ISSN
0018-5043
DOI
10.1055/a-1743-2988
language
English
LU publication?
yes
id
09d9caef-8215-4293-8d59-7f0f237f415f
date added to LUP
2022-05-20 11:02:21
date last changed
2024-05-30 12:03:53
@article{09d9caef-8215-4293-8d59-7f0f237f415f,
  abstract     = {{<p>Smoking is a well-known risk factor for Graves' ophthalmopathy (GO) in patients suffering from Graves' disease (GD). Cysteine-rich angiogenic inducer 61 (CYR61), which has multiple physiological functions, has been shown to be associated with GD and GO. In this study, we aimed to investigate the association between smoking and CYR61 concentrations in GD patients with and without GO. Serum CYR61 was measured by ELISA. The association between CYR61 concentration and GO was assessed with binary logistic regression in all patients and in subgroups of smokers and nonsmokers. The Spearman correlation coefficient was used to determine the correlations between CYR61 concentration and clinical parameters. CYR61 levels were significantly higher in GD patients with GO than in patients without GO, in smokers than in nonsmokers and in individuals older than 50 years than in those younger than 50 years. The subgroup of GO smokers had the highest CYR61 levels [median (IQR), 119 pg/ml (129.8)], compared with GO nonsmokers [84.2 pg/ml (90.8), p=0.04], no GO smokers [88.9 pg/ml (109.8), p=0.01] and no GO nonsmokers [79.4 pg/ml (129.89), p=0.003]. For each unit increase in CYR61 concentration, the odds of having GO in smokers significantly and independently increased by 1% (OR=1.010; 95% CI: 1.002-1.018, p=0.012). In conclusion, our results indicate that smoking and age increase serum CYR61 levels in patients with GD and GO. The role of CYR61 as a predictor of GO in patients with GD should be evaluated in prospective studies.</p>}},
  author       = {{Cerri, Perparim and Shahida, Bushra and Lantz, Mikael and Planck, Tereza}},
  issn         = {{0018-5043}},
  keywords     = {{CCN1; CYR61; Graves' disease; Graves' ophthalmopathy; immediate early genes; smoking}},
  language     = {{eng}},
  month        = {{03}},
  number       = {{3}},
  pages        = {{168--174}},
  publisher    = {{Georg Thieme Verlag}},
  series       = {{Hormone and Metabolic Research}},
  title        = {{Serum CYR61 Levels are Associated with Graves' Ophthalmopathy and Smoking in Patients with Graves' Disease}},
  url          = {{http://dx.doi.org/10.1055/a-1743-2988}},
  doi          = {{10.1055/a-1743-2988}},
  volume       = {{54}},
  year         = {{2021}},
}